(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
5 May 2011 (05.05.2011)

PCT

(10) International Publication Number
WO 2011/051307 A1

(51) International Patent Classification:
A61K 39/395 (2006.01) *G01N 33/574* (2006.01)
C07K 16/46 (2006.01)

(21) International Application Number:
PCT/EP2010/066207

(22) International Filing Date:
27 October 2010 (27.10.2010)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
09174104.1 27 October 2009 (27.10.2009) EP
61/255,290 27 October 2009 (27.10.2009) US

(71) Applicant *(for all designated States except US)*: **MICROMET AG** [DE/DE]; Staffelseestr. 2, 81477 Munich (DE).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **NAGORSEN, Dirk** [DE/DE]; c/o Micromet AG, Staffelseestrasse 2, 81477 Munich (DE). **KUFER, Peter** [DE/DE]; c/o Micromet AG, Staffelseestrasse 2, 81477 Munich (DE). **ZUGMAIER, Gerhard** [DE/DE]; c/o Micromet AG, Staffelseestrasse 2, 81477 Munich (DE). **BAEUERLE, Patrick** [DE/DE]; c/o Micromet AG, Staffelseestrasse 2, 81477 Munich (DE).

(74) Agents: **WEINZIERL, Gerhard** et al.; Schiweck, Weinzierl & Koch, Landsberger Strasse 98, 80339 Munich (DE).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

— *with sequence listing part of description (Rule 5.2(a))*

WO 2011/051307 A1

(54) **Title**: DOSAGE REGIMEN FOR ADMINISTERING A CD19XCD3 BISPECIFIC ANTIBODY

(57) **Abstract**: The present invention relates to a method for assessing (analyzing) the risk of potential adverse effects for a human patient mediated by the administration of a CD19xCD3 bispecific antibody to said patient comprising determining the ratio of B cells to T cells of said patient, wherein a ratio of about 1:5 or lower is indicative for a risk of potential adverse effects for said patient. Accordingly, the present invention relates a method (dosage regimen) for administering a CD19x CD3 bispecific antibody to a human patient having a B :T cell ratio of about 1:5 or lower, comprising (a) administering a first dose of said antibody for a first period of time; and consecutively (b) administering a second dose of said antibody for a second period of time, wherein said second dose exceeds said first dose.In some embodiments, a third dose of said antibody is administered for a third period of time. This dosage regimen can be applied in methods for treating malignant CD19 positive lymphocytes or for ameliorating and/or preventing an adverse effect mediated by the administration of said bispecific antibody. The present invention also relates to the use of a CD19x CD3 bispecific antibody for the preparation of a pharmaceutical composition to be used in a method of the present invention. A pharmaceutical package or kit comprising a first dose and a second dose and optionally a third dose of said antibody as defined in the methods/dosage regimen of the present invention is disclosed as well.